Jasper Therapeutics Faced Class Action Lawsuit Over Securities Purchases

Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Jasper Therapeutics securities between November 30, 2023 and July 3, 2025. Those who purchased securities during this period may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement. To join the lawsuit, visit https://rosenlegal.com/submit-form/?case_id=45109 or call Phillip Kim, Esq. at 866-767-3653.

NEW YORK, Sept. 12, 2025 — Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Jasper Therapeutics, Inc. (NASDAQ: JSPR) securities between November 30, 2023 and July 3, 2025. Those who purchased securities during this period may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement.

The lawsuit alleges that Jasper Therapeutics made materially false and misleading statements and/or failed to disclose that the company lacked the controls and procedures necessary to ensure that third-party manufacturers were manufacturing products in full accordance with cGMP regulations. This failure increased the risk that results of ongoing studies would be confounded, negatively impacting the regulatory and commercial prospects of Jasper's products, including briquilimab. The lawsuit further alleges that these issues were not disclosed, leading to overstated business and financial prospects.

Investors who purchased Jasper Therapeutics securities during the specified period are encouraged to join the class action lawsuit. To join, visit https://rosenlegal.com/submit-form/?case_id=45109 or call Phillip Kim, Esq. toll-free at 866-767-3653. The deadline to request appointment as lead plaintiff is November 18, 2025.

Rosen Law Firm is a global investor rights law firm with a track record of success in securities class actions and shareholder derivative litigation. The firm has recovered hundreds of millions of dollars for investors worldwide.